Beyond Small Molecules: Gene Therapy and Protein Replacement in the Friedreich’s Ataxia Drug Market
The approval of small-molecule therapies that manage oxidative stress was a monumental victory for patients living with Friedreich’s Ataxia (FA). However, drugs that treat the symptoms and slow the progression do not cure the underlying genetic defect. As the biotechnology sector pushes the boundaries of molecular medicine, the Friedreich’s Ataxia Drug Market is actively pivoting...
0 التعليقات 0 المشاركات 92 مشاهدة 0 معاينة